ZBIO — Zenas Biopharma Cashflow Statement
0.000.00%
- $498.25m
- $147.48m
- $5.00m
- 27
- 11
- 39
- 14
Annual cashflow statement for Zenas Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -119 | -37.1 | -157 |
Depreciation | |||
Non-Cash Items | 45.6 | 14.5 | 11.7 |
Unusual Items | |||
Purchased R&D | |||
Other Non-Cash Items | |||
Changes in Working Capital | 7.97 | -8.04 | 25.4 |
Change in Prepaid Expenses | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Cash from Operating Activities | -65.7 | -30.5 | -120 |
Capital Expenditures | -2.2 | -0.017 | -0.131 |
Purchase of Fixed Assets | |||
Purchase / Acquisition of Intangibles | |||
Other Investing Cash Flow Items | — | — | -30.4 |
Sale/Maturity of Investment | |||
Purchase of Investments | |||
Cash from Investing Activities | -2.2 | -0.017 | -30.6 |
Financing Cash Flow Items | — | — | -6.33 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 59.4 | 20.1 | 413 |
Foreign Exchange Effects | |||
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | -8.5 | -10.4 | 263 |